Travere Therapeutics, Inc.TVTXNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank79
3Y CAGR-3.2%
5Y CAGR+9.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-3.2%/yr
vs +16.4%/yr prior
5Y CAGR
+9.3%/yr
Recent deceleration
Acceleration
-19.6pp
Decelerating
Percentile
P79
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $206.01M | -27.1% |
| 2024 | $282.70M | +15.4% |
| 2023 | $244.99M | +7.8% |
| 2022 | $227.33M | +13.0% |
| 2021 | $201.16M | +52.7% |
| 2020 | $131.77M | -6.5% |
| 2019 | $140.96M | +13.9% |
| 2018 | $123.76M | +58.3% |
| 2017 | $78.17M | +10.3% |
| 2016 | $70.85M | - |